iShares Biotechnology ETF (IBB)
165.54
+3.29 (+2.03%)
USD |
Jul 28, 13:19
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.46% | 0.04% | 10.73B | 2.844M |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.17% | 34.00% | -463.12M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to track the investment results of the ICE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. The underlying index measures the performance of U.S.-listed securities of companies that are classified according to the ICE Uniform Sector Classification schema within the Biotechnology Sub-Industry Group and that also meet other eligibility criteria determined by the index provider. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| ICE Biotechnology TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 13.51 yrs |
| Jennifer Hsui | 8.92 yrs |
| Alan Mason | 5.21 yrs |
| Amy Whitelaw | 2.92 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
98
-463.12M
-4.645B
Category Low
7.623B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of June 30, 2021
Performance Versus Category
As of July 27, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of July 27, 2021.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Moderna Inc | 8.74% | 343.60 | 4.60% |
| Amgen Inc | 7.96% | 244.05 | -0.26% |
| Gilead Sciences Inc | 6.56% | 69.55 | 0.90% |
| Illumina Inc | 5.44% | 493.00 | 1.39% |
| Regeneron Pharmaceuticals Inc | 4.44% | 583.56 | 0.44% |
| Vertex Pharmaceuticals Inc | 3.91% | 202.15 | -0.35% |
| BioNTech SE ADR | 3.85% | 299.44 | 5.44% |
| Biogen Inc | 3.79% | 331.08 | -0.86% |
| IQVIA Holdings Inc | 3.57% | 243.93 | 0.31% |
| Mettler-Toledo International Inc | 2.56% | 1496.01 | 1.09% |
News
Headline
Wire
Time (ET)
Basic Info
| Investment Strategy | |
| The investment seeks to track the investment results of the ICE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. The underlying index measures the performance of U.S.-listed securities of companies that are classified according to the ICE Uniform Sector Classification schema within the Biotechnology Sub-Industry Group and that also meet other eligibility criteria determined by the index provider. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| ICE Biotechnology TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 13.51 yrs |
| Jennifer Hsui | 8.92 yrs |
| Alan Mason | 5.21 yrs |
| Amy Whitelaw | 2.92 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (7-28-21) | 0.17% |
| 30-Day SEC Yield (3-31-20) | Upgrade |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 30.89 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of July 23, 2021
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 2/5/2001 |
| Last Annual Report Date | 3/31/2021 |
| Last Prospectus Date | 6/21/2021 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan |
|
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)